(capsaicin cream 0.075%)
Axsain® (capsaicin cream 0.075%) is indicated:
After long-term treatment with Axsain® (up to two years), burning or stinging at the site of application was recorded in only 9% of patients.4
Axsain® (capsaicin cream 0.075%) is for topical application1
Capsaicin binds to skin-based nociceptors, initially causing localised neurogenic inflammation then cumulatively depleting inflammatory agents including Substance P.1
For the full list of excipients, see Section 6.1 of the Summary of Product Characteristics.
Cephalon UK Limited
Ridings Point, Whistler Drive
Castleford, West Yorkshire
Marketing Authorisation Number(s)
1 Axsain® (capsaicin cream 0.075%) Summary of Product Characteristics.
2 Tesfaye S, Selvarajah D. Recent advances in the pharmacological management of painful diabetic neuropathy. S Afr J Diabetes Vasc Dis 2010; 7: 139-142.
3 Boulton AJM. Management of diabetic peripheral neuropathy. Clin Diabetes 2005; 23: 9-15.
4 Watson CP, Tyler KL, Bickers JR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of portherpetic neuralgia. Clin Ther 1993; 15: 510-526.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.